European Biotech IPOs Go Global
This article was originally published in Start Up
Executive Summary
European biotech IPOs, spurred by the emergence of new European high tech exchanges such as Germany's Neuer Markt and France's Nouveau Marche, reached something of a milestone last year: while there were considerably fewer biotech IPOs completed on these exchanges, for the first time, the average amount raised in these deals was higher than those completed on NASDAQ.
You may also be interested in...
Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue
While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.
Biopharma VCs Move to the Middle in 2006
While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.
Biopharma IPOs Start Swing Back to Nasdaq
The trend of biopharma IPOs eschewing Nasdaq for European and other exchanges reverses modestly in 2006.